NVV1 Stock Chart & Stats
€6.60
€0.02(0.32%)
At close: 4:00 PM EDT
€6.60
€0.02(0.32%)
Day’s Range― - ―
52-Week Range€5.44 - €10.03
Previous CloseN/A
Volume826.00
Average Volume (3M)2.98K
Market Cap
€1.34B
Enterprise Value€1.13K
Total Cash (Recent Filing)€719.34M
Total Debt (Recent Filing)€295.60M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,945,720
10 Day Avg. Volume2,086
30 Day Avg. Volume2,984
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.36Price Target Upside72.12% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.55
Revenue Forecast (FY)€317.95M
Bulls Say, Bears Say
Bulls Say
Partnering And Royalty GrowthStrong growth in partner-related revenue validates the Matrix-M platform and broadens Novavax’s monetization model beyond direct vaccine sales, potentially supporting more recurring royalties, milestones and supply revenue over the medium term.
Liquidity RunwayThe substantial cash and receivables balance, supplemented by partner funding and credit access, gives management time to advance vaccine programs and pursue partnerships without an immediate need for additional equity financing.
Structural Cost ReductionLower operating expenses improve the scalability of future partner and royalty revenue. Continued cost discipline, including a targeted 2028 R&D and SG&A range of $150M–$200M, supports management’s profitability roadmap.
Bears Say
Persistent Negative EquityA sustained equity deficit leaves less balance-sheet protection for creditors and shareholders, can increase dependence on liabilities or partners, and may constrain strategic flexibility if operating performance weakens.
Ongoing Cash BurnMulti-year negative operating and free cash flow indicates that the current business is not yet self-funding. Continued investment in development and commercialization therefore depends on cash reserves, partners or external financing.
Low Direct Product SalesLimited direct product revenue reduces Novavax’s control over commercial execution and leaves results more dependent on partner decisions, licensing conversions and milestone timing, which can make future revenue less predictable.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €5.44 and its highest was €10.03 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.34B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -€0.277 earnings per share for the quarter, beating the consensus estimate of -€0.329 by €0.052.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.2.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.277 in its last earnings report, beating expectations of -€0.329. Following the earnings report the stock price went up 0.61%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€11.36 (72.12% Upside)
€11.36 (72.12% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 94%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€11.36
▲(72.12% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―